Cargando…
An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development
Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (R...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309007/ https://www.ncbi.nlm.nih.gov/pubmed/34371762 http://dx.doi.org/10.3390/pharmaceutics13071071 |
_version_ | 1783728419497836544 |
---|---|
author | Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Kozma, Gábor Kónya, Zoltán Csóka, Ildikó |
author_facet | Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Kozma, Gábor Kónya, Zoltán Csóka, Ildikó |
author_sort | Németh, Zsófia |
collection | PubMed |
description | Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (RA)-based study was performed to determine the Critical Material Attributes and the Critical Process Parameters of an “intermediate” active pharmaceutical ingredient-free liposome formulation prepared via the thin-film hydration method, collect the Critical Quality Attributes of the future carrier system and show the process of narrowing a general initial RA for a specific case. The theoretical liposome design was proved through experimental models. The investigated critical factors covered the working temperature, the ratio between the wall-forming agents (phosphatidylcholine and cholesterol), the PEGylated phospholipid content (DPPE-PEG(2000)), the type of the hydration media (saline or phosphate-buffered saline solutions) and the cryoprotectants (glucose, sorbitol or trehalose). The characterisation results (size, surface charge, thermodynamic behaviours, formed structure and bonds) of the prepared liposomes supported the outcomes of the updated RA. The findings can be used as a basis for a particular study with specified circumstances. |
format | Online Article Text |
id | pubmed-8309007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83090072021-07-25 An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Kozma, Gábor Kónya, Zoltán Csóka, Ildikó Pharmaceutics Article Liposomal formulation development is a challenging process. Certain factors have a critical influence on the characteristics of the liposomes, and even the relevant properties can vary based on the predefined interests of the research. In this paper, a Quality by Design-guided and Risk Assessment (RA)-based study was performed to determine the Critical Material Attributes and the Critical Process Parameters of an “intermediate” active pharmaceutical ingredient-free liposome formulation prepared via the thin-film hydration method, collect the Critical Quality Attributes of the future carrier system and show the process of narrowing a general initial RA for a specific case. The theoretical liposome design was proved through experimental models. The investigated critical factors covered the working temperature, the ratio between the wall-forming agents (phosphatidylcholine and cholesterol), the PEGylated phospholipid content (DPPE-PEG(2000)), the type of the hydration media (saline or phosphate-buffered saline solutions) and the cryoprotectants (glucose, sorbitol or trehalose). The characterisation results (size, surface charge, thermodynamic behaviours, formed structure and bonds) of the prepared liposomes supported the outcomes of the updated RA. The findings can be used as a basis for a particular study with specified circumstances. MDPI 2021-07-13 /pmc/articles/PMC8309007/ /pubmed/34371762 http://dx.doi.org/10.3390/pharmaceutics13071071 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Kozma, Gábor Kónya, Zoltán Csóka, Ildikó An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development |
title | An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development |
title_full | An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development |
title_fullStr | An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development |
title_full_unstemmed | An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development |
title_short | An Updated Risk Assessment as Part of the QbD-Based Liposome Design and Development |
title_sort | updated risk assessment as part of the qbd-based liposome design and development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309007/ https://www.ncbi.nlm.nih.gov/pubmed/34371762 http://dx.doi.org/10.3390/pharmaceutics13071071 |
work_keys_str_mv | AT nemethzsofia anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT pallagiedina anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT dobodorinagabriella anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT kozmagabor anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT konyazoltan anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT csokaildiko anupdatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT nemethzsofia updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT pallagiedina updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT dobodorinagabriella updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT kozmagabor updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT konyazoltan updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment AT csokaildiko updatedriskassessmentaspartoftheqbdbasedliposomedesignanddevelopment |